Zacks Investment Research on MSN
Can DefenCath continue to aid CorMedix's long-term growth ahead?
CorMedix’s CRMD lead therapy, DefenCath (taurolidine + heparin), is currently the company’s majority revenue driver. The FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback